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Abstract
Though many women in need of access to HIV preventive regimes are pregnant, there is a dearth of data to guide
these care decisions. While oral pre-exposure prophylaxis (PrEP) has been shown to prevent HIV infection in numerous
high-risk populations, pregnant women have been excluded from all major prospective trials. We propose for ethical
examination a theoretical trial—a prospective, observational study of PrEP for pregnant women at risk for HIV in sub-
Saharan Africa—highlighting an ethical tradeoff that characterizes issues faced for advancing research in pregnancy.
On the one hand, an “opportunistic” study design has certain ethical advantages: as formally construed, the research
activity usually begins after decisions to use PrEP during pregnancy are made in the clinical setting. This minimizes
research risks and avoids ethical problems that a randomized controlled trial (RCT) comparing PrEP to placebo would
entail, particularly withholding care proven beneficial in other populations. On the other hand, observational studies
yield less precise information than RCTs. This raises a broader question about the pace of research with pregnant
women, as it typically takes many years after a drug’s approval for use in the general population to determine safety of
the medication in pregnancy. Such delays can have the effect of making it impossible to ethically conduct an RCT with
pregnant women, reducing the likelihood that the research community is able to obtain robust, pregnancy-specific
evidence. While an observational cohort is potentially the most ethically and scientifically justified research design to
study PrEP in pregnancy, earlier involvement of pregnant women in studies of newer preventives may lead to
evidence that is more timely and robust.
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Case background
Approximately 17.8 million women are living with HIV
worldwide [1], and millions more are at risk of infection.
Given pregnancy rates in general, and that unprotected
intercourse is a leading HIV risk factor for women, many
women in need of HIV preventive regimes are pregnant.
Additionally, incident infection with HIV during preg-
nancy is associated with high rates of maternal-to-child
transmission [2]. Although research on prevention of
maternal-to-child transmission (PMTCT) of HIV has
contributed to an evidence base for antiretroviral use in
pregnancy, there is a dearth of data on how to best pre-
vent acquisition of HIV in pregnant women.
Pre-exposure prophylaxis (PrEP) has been shown to pre-
vent HIV infection in numerous high-risk populations, yet
little is known about its use in pregnant populations. Preg-
nancy has been an exclusion criteria from all major trials
of PrEP in Africa e.g., [3, 4], and women who become
pregnant while participating in such trials are required to
discontinue medication. The result has been conflicting
guidance on whether and when pregnant women at risk
for HIV should use PrEP for prevention [5, 6]. Given the
physiological changes that occur during pregnancy, re-
search is critically needed to establish appropriate guide-
lines for safe and effective use of PrEP during pregnancy.
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Future study, however, is uncertain due to debate
about when and under what circumstances pregnant
women should be involved in such research. The medi-
cations used in PrEP, including tenofovir (TDF) and
tenofovir-emtricitabine (TDF-FTC) have been studied
for PMTCT among pregnant women living with HIV
and hepatitis B, and among women with incident preg-
nancy during PrEP trials; this limited data suggests these
medications are generally safe in pregnancy [7–9],
though further research is indicated on some outcomes
[7]. On the one hand, such data are reassuring and we
are now, presumably, better placed to gather robust,
pregnancy-specific data. Yet the interim establishment of
efficacy in non-pregnant individuals ushers in new eth-
ical complexities, namely the challenges of gathering ro-
bust data in pregnancy after positive trials in non-
pregnant populations.
We propose for consideration a prospective study of
oral PrEP for pregnant women at risk for HIV in sub-
Saharan Africa. While the case we propose is theoretical,
a study is in fact currently under development by the
International Maternal Pediatric Adolescent AIDS Clin-
ical Trials (IMPAACT) Network, IMPAACT 2009 [10].
IMPAACT 2009 is an observational cohort study com-
paring pregnancy outcomes among women at risk for
HIV who are taking oral PrEP to women who decline
PrEP during the antenatal period. If implemented, this
would be the first large prospective study of PrEP in
pregnant women.
Ethical discussion
Advancing the study of PrEP in pregnancy raises several
ethical considerations in the current context, particularly
ethical tradeoffs related to the choice of study design. An
observational design has certain ethical advantages. First,
the approach utilized is often “opportunistic”: as formally
construed, research activity begins after decisions about
use or non-use of PrEP are made in the clinical setting.
Understood this way, the risks attributed to the research
itself are minimal, limited to monitoring and follow-up;
thus, the ethical and regulatory complexities of risk/bene-
fit tradeoffs that often characterize interventional studies
can be avoided. Second, an observational study avoids the
ethical challenges that a randomized controlled study
(RCT) comparing PrEP to placebo would entail, particu-
larly withholding care proven beneficial in other popula-
tions. Indeed, a placebo-controlled RCT may now be
difficult or impossible to justify given the robust evidence
for PrEP in non-pregnant populations.
Yet, there are also disadvantages to such a design. Ob-
servational studies may not yield as precise data—parti-
cularly about rare events—as a randomized trial would.
Thus, while an observational cohort can be an important
workaround, it raises a broader question about the pace
of research with pregnant women and the costs of delay-
ing or avoiding prospective research, however ethically
complex. Observational research in pregnancy most
often occurs after licensure; estimates suggest that the
determination of a medication’s safety during pregnancy
takes an average of 27 years following the drug’s ap-
proval [11]. Delays in conducting research with pregnant
women—problematic in their own right—can have the
further effect of making it impossible to ethically con-
duct an RCT with pregnant women, reducing the likeli-
hood there will ever be robust, pregnancy-specific
evidence. To the extent delays can enroot gaps in the
evidence base, they indicate an ethical cost to caution.
As we move forward in prevention efforts (and with
newer technologies, such as the vaginal ring), it is im-
portant to consider not just how clinical trials with preg-
nant women could be conducted, but when in the
research and development cycle pregnant women should
be included. Clearly, delaying enrollment of pregnant
women in prevention studies allows accumulation of
pregnancy safety data through inadvertent exposures,
and also permits the research community to avoid the
ethical challenges of intentional exposure of pregnant
women to interventions whose risks and benefits are un-
clear. However, these delays can also raise new ethical
barriers to the conduct of studies that would provide ro-
bust, pregnancy-specific data. Given the costs of delay,
timely inclusion of pregnant women must be addressed
in developing an HIV prevention research agenda that
adequately and ethically attends to the interests of preg-
nant women and their future offspring.
Conclusions
There is an urgent need for HIV preventives during
pregnancy; a prospective clinical trial of PrEP in preg-
nant women is an important step in meeting this need.
While an observational cohort is potentially the most
ethically and scientifically justified research design to
study PrEP, earlier involvement of pregnant women in
studies of newer preventives going forward may lead to
evidence that is more timely and more robust. Address-
ing the ethical complexities of intervention research is
therefore a pressing priority.
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